DPP-4抑制-话题@MedSci

#DPP-4抑制#

46篇内容 | 1743人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1784716, encodeId=d1281e8471669, content=<a href='/topic/show?id=6a926214b8' target=_blank style='color:#2F92EE;'>#DPP-4抑制#</a>, objectTitle=Cardiovasc Diabetol：使用SGLT2i、GLP1RA和DPP-4抑制剂治疗的2型糖尿病患者发生房颤的风险, objectType=article, longId=735642, objectId=ed39e3564211, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ed39e3564211, replyNumber=0, likeNumber=102, createdTime=2023-04-25, rootId=0, userName=xue8602, userId=d139492, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ed39e3564211, moduleTitle=Cardiovasc Diabetol：使用SGLT2i、GLP1RA和DPP-4抑制剂治疗的2型糖尿病患者发生房颤的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ed39e3564211)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1784718, encodeId=27931e8471862, content=<a href='/topic/show?id=6a926214b8' target=_blank style='color:#2F92EE;'>#DPP-4抑制#</a>, objectTitle=【每日播报】-磺脲类药物联合DPP-4抑制剂的疗效, objectType=article, longId=738851, objectId=9b3ae388512b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9b3ae388512b, replyNumber=0, likeNumber=67, createdTime=2022-12-03, rootId=0, userName=xue8602, userId=d139492, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9b3ae388512b, moduleTitle=【每日播报】-磺脲类药物联合DPP-4抑制剂的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9b3ae388512b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1784717, encodeId=01811e84717b7, content=<a href='/topic/show?id=6a926214b8' target=_blank style='color:#2F92EE;'>#DPP-4抑制#</a>, objectTitle=SGLT2抑制剂、DPP-4抑制剂和磺酰脲类药物在糖尿病酮症酸中毒方面的安全性比较, objectType=article, longId=736572, objectId=7caae365721d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7caae365721d, replyNumber=0, likeNumber=94, createdTime=2023-02-01, rootId=0, userName=xue8602, userId=d139492, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7caae365721d, moduleTitle=SGLT2抑制剂、DPP-4抑制剂和磺酰脲类药物在糖尿病酮症酸中毒方面的安全性比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7caae365721d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1784714, encodeId=53bc1e84714d0, content=<a href='/topic/show?id=6a926214b8' target=_blank style='color:#2F92EE;'>#DPP-4抑制#</a>, objectTitle=Cardiovasc Diabetol：GLP-1激动剂 vs SGLT-2抑制剂 vs DPP-4抑制剂对T2DM患者心肾结局的影响, objectType=article, longId=301367, objectId=c4b830136e91, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c4b830136e91, replyNumber=0, likeNumber=73, createdTime=2022-09-19, rootId=0, userName=xue8602, userId=d139492, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c4b830136e91, moduleTitle=Cardiovasc Diabetol：GLP-1激动剂 vs SGLT-2抑制剂 vs DPP-4抑制剂对T2DM患者心肾结局的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c4b830136e91)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1784713, encodeId=04d81e8471300, content=<a href='/topic/show?id=6a926214b8' target=_blank style='color:#2F92EE;'>#DPP-4抑制#</a>, objectTitle=JAMA子刊：GLP-1受体激动剂与DPP-4抑制剂的使用与2型糖尿病和晚期慢性肾病患者死亡率的关系, objectType=article, longId=300317, objectId=525d30031e63, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=525d30031e63, replyNumber=0, likeNumber=191, createdTime=2022-04-30, rootId=0, userName=xue8602, userId=d139492, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=525d30031e63, moduleTitle=JAMA子刊：GLP-1受体激动剂与DPP-4抑制剂的使用与2型糖尿病和晚期慢性肾病患者死亡率的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=525d30031e63)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1784715, encodeId=07721e84715f3, content=<a href='/topic/show?id=6a926214b8' target=_blank style='color:#2F92EE;'>#DPP-4抑制#</a>, objectTitle=Cardiovasc Diabetol：DPP-4抑制剂、GLP-1受体激动剂和SGLT-2抑制剂对心肾结局的影响, objectType=article, longId=723796, objectId=c62be2379617, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c62be2379617, replyNumber=0, likeNumber=113, createdTime=2022-09-28, rootId=0, userName=xue8602, userId=d139492, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c62be2379617, moduleTitle=Cardiovasc Diabetol：DPP-4抑制剂、GLP-1受体激动剂和SGLT-2抑制剂对心肾结局的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c62be2379617)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1784712, encodeId=33b91e84712c0, content=<a href='/topic/show?id=6a926214b8' target=_blank style='color:#2F92EE;'>#DPP-4抑制#</a>, objectTitle=Clin Pharmacol Ther ：2型糖尿病患者中GLP-1 RA和DPP-4抑制剂的使用与肠梗阻风险增加相关, objectType=article, longId=218302, objectId=3ada21830258, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3ada21830258, replyNumber=0, likeNumber=82, createdTime=2021-11-30, rootId=0, userName=xue8602, userId=d139492, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3ada21830258, moduleTitle=Clin Pharmacol Ther ：2型糖尿病患者中GLP-1 RA和DPP-4抑制剂的使用与肠梗阻风险增加相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3ada21830258)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1784711, encodeId=38931e84711d1, content=<a href='/topic/show?id=6a926214b8' target=_blank style='color:#2F92EE;'>#DPP-4抑制#</a>, objectTitle=BMJ子刊：基于真实世界研究，长期使用DPP-4抑制剂对2型糖尿病患者的安全性和有效性, objectType=article, longId=205874, objectId=7eb72058e492, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7eb72058e492, replyNumber=0, likeNumber=141, createdTime=2021-08-28, rootId=0, userName=xue8602, userId=d139492, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7eb72058e492, moduleTitle=BMJ子刊：基于真实世界研究，长期使用DPP-4抑制剂对2型糖尿病患者的安全性和有效性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7eb72058e492)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1784710, encodeId=3caa1e8471052, content=<a href='/topic/show?id=6a926214b8' target=_blank style='color:#2F92EE;'>#DPP-4抑制#</a>, objectTitle=Diabetes Obes Metab：2型糖尿病患者服用DPP-4抑制剂与肺炎风险的关系, objectType=article, longId=198041, objectId=482f198041a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=482f198041a4, replyNumber=0, likeNumber=90, createdTime=2021-01-30, rootId=0, userName=xue8602, userId=d139492, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=482f198041a4, moduleTitle=Diabetes Obes Metab：2型糖尿病患者服用DPP-4抑制剂与肺炎风险的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=482f198041a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1784709, encodeId=89791e84709be, content=<a href='/topic/show?id=6a926214b8' target=_blank style='color:#2F92EE;'>#DPP-4抑制#</a>, objectTitle=Metabolism：DPP-4抑制剂在2型糖尿病治疗中的疗效和安全性, objectType=article, longId=196067, objectId=8fa119606e77, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8fa119606e77, replyNumber=0, likeNumber=86, createdTime=2021-05-19, rootId=0, userName=xue8602, userId=d139492, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8fa119606e77, moduleTitle=Metabolism：DPP-4抑制剂在2型糖尿病治疗中的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8fa119606e77)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1784706, encodeId=68341e84706ff, content=<a href='/topic/show?id=6a926214b8' target=_blank style='color:#2F92EE;'>#DPP-4抑制#</a>, objectTitle=客官厉害了！国产原创DPP-4抑制剂盛格列汀“免二进三”, objectType=article, longId=183020, objectId=e12c1830202d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e12c1830202d, replyNumber=0, likeNumber=87, createdTime=2020-02-29, rootId=0, userName=xue8602, userId=d139492, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e12c1830202d, moduleTitle=客官厉害了！国产原创DPP-4抑制剂盛格列汀“免二进三”, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e12c1830202d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1784708, encodeId=4bba1e847083b, content=<a href='/topic/show?id=6a926214b8' target=_blank style='color:#2F92EE;'>#DPP-4抑制#</a>, objectTitle=Diabetes Obes Metab：2型糖尿病患者DPP-4抑制剂治疗与COVID-19, objectType=article, longId=194932, objectId=a64319493248, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a64319493248, replyNumber=0, likeNumber=77, createdTime=2021-02-11, rootId=0, userName=xue8602, userId=d139492, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a64319493248, moduleTitle=Diabetes Obes Metab：2型糖尿病患者DPP-4抑制剂治疗与COVID-19, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a64319493248)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1784707, encodeId=44ab1e84707bc, content=<a href='/topic/show?id=6a926214b8' target=_blank style='color:#2F92EE;'>#DPP-4抑制#</a>, objectTitle=DPP-4抑制剂临床应用专家指导建议解读 | CDS2019, objectType=article, longId=183694, objectId=83b71836947d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=83b71836947d, replyNumber=0, likeNumber=114, createdTime=2020-05-01, rootId=0, userName=xue8602, userId=d139492, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=83b71836947d, moduleTitle=DPP-4抑制剂临床应用专家指导建议解读 | CDS2019, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=83b71836947d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1784703, encodeId=92321e84703dd, content=<a href='/topic/show?id=6a926214b8' target=_blank style='color:#2F92EE;'>#DPP-4抑制#</a>, objectTitle=为什么DPP-4抑制剂是二甲双胍加药的优选？, objectType=article, longId=176161, objectId=26211e6161fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=26211e6161fd, replyNumber=0, likeNumber=90, createdTime=2020-04-30, rootId=0, userName=xue8602, userId=d139492, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=26211e6161fd, moduleTitle=为什么DPP-4抑制剂是二甲双胍加药的优选？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=26211e6161fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1784705, encodeId=350b1e84705b4, content=<a href='/topic/show?id=6a926214b8' target=_blank style='color:#2F92EE;'>#DPP-4抑制#</a>, objectTitle=DPP-4抑制剂——心血管疾病史患者的二联用药优选, objectType=article, longId=177142, objectId=867b1e714287, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=867b1e714287, replyNumber=0, likeNumber=71, createdTime=2019-08-20, rootId=0, userName=xue8602, userId=d139492, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=867b1e714287, moduleTitle=DPP-4抑制剂——心血管疾病史患者的二联用药优选, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=867b1e714287)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1784704, encodeId=f4f01e847047b, content=<a href='/topic/show?id=6a926214b8' target=_blank style='color:#2F92EE;'>#DPP-4抑制#</a>, objectTitle=DPP-4抑制剂——二联用药中的换药优选, objectType=article, longId=176240, objectId=7a4b1e6240bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7a4b1e6240bd, replyNumber=0, likeNumber=84, createdTime=2020-01-12, rootId=0, userName=xue8602, userId=d139492, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7a4b1e6240bd, moduleTitle=DPP-4抑制剂——二联用药中的换药优选, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7a4b1e6240bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1784702, encodeId=de4b1e84702e9, content=<a href='/topic/show?id=6a926214b8' target=_blank style='color:#2F92EE;'>#DPP-4抑制#</a>, objectTitle=DPP-4抑制剂，二甲双胍加药优选, objectType=article, longId=176117, objectId=73031e611783, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=73031e611783, replyNumber=0, likeNumber=72, createdTime=2020-04-10, rootId=0, userName=xue8602, userId=d139492, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=73031e611783, moduleTitle=DPP-4抑制剂，二甲双胍加药优选, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=73031e611783)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1784701, encodeId=72081e847017d, content=<a href='/topic/show?id=6a926214b8' target=_blank style='color:#2F92EE;'>#DPP-4抑制#</a>, objectTitle=AP&T： DPP-4抑制剂维达列汀可抑制胃调节并增加胰高血糖素样肽-1血浆水平, objectType=article, longId=162307, objectId=fc3b16230e8f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc3b16230e8f, replyNumber=0, likeNumber=153, createdTime=2019-10-07, rootId=0, userName=xue8602, userId=d139492, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc3b16230e8f, moduleTitle=AP&T： DPP-4抑制剂维达列汀可抑制胃调节并增加胰高血糖素样肽-1血浆水平, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fc3b16230e8f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1784698, encodeId=629c1e8469815, content=<a href='/topic/show?id=6a926214b8' target=_blank style='color:#2F92EE;'>#DPP-4抑制#</a>, objectTitle=BMJ：DPP-4抑制剂以及GLP-1激动剂或导致糖尿病患者胆管癌风险增加, objectType=article, longId=155614, objectId=db9d15561414, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=db9d15561414, replyNumber=0, likeNumber=72, createdTime=2019-01-30, rootId=0, userName=xue8602, userId=d139492, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=db9d15561414, moduleTitle=BMJ：DPP-4抑制剂以及GLP-1激动剂或导致糖尿病患者胆管癌风险增加, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=db9d15561414)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1784700, encodeId=22441e8470097, content=<a href='/topic/show?id=6a926214b8' target=_blank style='color:#2F92EE;'>#DPP-4抑制#</a>, objectTitle=DPP-4抑制剂临床应用专家共识, objectType=article, longId=157552, objectId=86a515e552ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=86a515e552ea, replyNumber=0, likeNumber=77, createdTime=2019-09-18, rootId=0, userName=xue8602, userId=d139492, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=86a515e552ea, moduleTitle=DPP-4抑制剂临床应用专家共识, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=86a515e552ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

DPP-4抑制

2020-05-29

xue8602 (审核中...)

前往app查看评论内容

#DPP-4抑制#

Cardiovasc Diabetol：使用SGLT2i、GLP1RA和DPP-4抑制剂治疗的2型糖尿病患者发生房颤的风险

2023-04-25

xue8602 (审核中...)

前往app查看评论内容

#DPP-4抑制#

【每日播报】-磺脲类药物联合DPP-4抑制剂的疗效

2022-12-03

xue8602 (审核中...)

前往app查看评论内容

#DPP-4抑制#

SGLT2抑制剂、DPP-4抑制剂和磺酰脲类药物在糖尿病酮症酸中毒方面的安全性比较

2023-02-01

xue8602 (审核中...)

前往app查看评论内容

#DPP-4抑制#

Cardiovasc Diabetol：GLP-1激动剂 vs SGLT-2抑制剂 vs DPP-4抑制剂对T2DM患者心肾结局的影响

2022-09-19

xue8602 (审核中...)

前往app查看评论内容

#DPP-4抑制#

JAMA子刊：GLP-1受体激动剂与DPP-4抑制剂的使用与2型糖尿病和晚期慢性肾病患者死亡率的关系

2022-04-30

xue8602 (审核中...)

前往app查看评论内容

#DPP-4抑制#

Cardiovasc Diabetol：DPP-4抑制剂、GLP-1受体激动剂和SGLT-2抑制剂对心肾结局的影响

2022-09-28

xue8602 (审核中...)

前往app查看评论内容

#DPP-4抑制#

Clin Pharmacol Ther ：2型糖尿病患者中GLP-1 RA和DPP-4抑制剂的使用与肠梗阻风险增加相关

2021-11-30

xue8602 (审核中...)

前往app查看评论内容

#DPP-4抑制#

BMJ子刊：基于真实世界研究，长期使用DPP-4抑制剂对2型糖尿病患者的安全性和有效性

2021-08-28

xue8602 (审核中...)

前往app查看评论内容

#DPP-4抑制#

Diabetes Obes Metab：2型糖尿病患者服用DPP-4抑制剂与肺炎风险的关系

2021-01-30

xue8602 (审核中...)

前往app查看评论内容

#DPP-4抑制#

Metabolism：DPP-4抑制剂在2型糖尿病治疗中的疗效和安全性

2021-05-19

xue8602 (审核中...)

前往app查看评论内容

#DPP-4抑制#

客官厉害了！国产原创DPP-4抑制剂盛格列汀“免二进三”

2020-02-29

xue8602 (审核中...)

前往app查看评论内容

#DPP-4抑制#

Diabetes Obes Metab：2型糖尿病患者DPP-4抑制剂治疗与COVID-19

2021-02-11

xue8602 (审核中...)

前往app查看评论内容

#DPP-4抑制#

DPP-4抑制剂临床应用专家指导建议解读 | CDS2019

2020-05-01

xue8602 (审核中...)

前往app查看评论内容

#DPP-4抑制#

为什么DPP-4抑制剂是二甲双胍加药的优选？

2020-04-30

xue8602 (审核中...)

前往app查看评论内容

#DPP-4抑制#

DPP-4抑制剂——心血管疾病史患者的二联用药优选

2019-08-20

xue8602 (审核中...)

前往app查看评论内容

#DPP-4抑制#

DPP-4抑制剂——二联用药中的换药优选

2020-01-12

xue8602 (审核中...)

前往app查看评论内容

#DPP-4抑制#

DPP-4抑制剂，二甲双胍加药优选

2020-04-10

xue8602 (审核中...)

前往app查看评论内容

#DPP-4抑制#

AP&T： DPP-4抑制剂维达列汀可抑制胃调节并增加胰高血糖素样肽-1血浆水平

2019-10-07

xue8602 (审核中...)

前往app查看评论内容

#DPP-4抑制#

BMJ：DPP-4抑制剂以及GLP-1激动剂或导致糖尿病患者胆管癌风险增加

2019-01-30

xue8602 (审核中...)

前往app查看评论内容

#DPP-4抑制#

DPP-4抑制剂临床应用专家共识

2019-09-18

科室
- - 订阅+
  - 更多科室
工具
服务